The massive EPS miss and revenue decline are overshadowed by non-cash warrant charges, but the underlying operating loss widened 45% YoY. Watch for the BEST1 data readout in September 2026 and LCA5 pivotal trial dosing in Q4 2026 as key catalysts. The Oberland financing provides near-term liquidity but adds debt. The stock may trade on pipeline milestones rather than current financials.
Price Chart
Executive Summary
Opus Genetics reported Q1 2026 EPS of -$0.75, a 212.5% miss vs consensus of -$0.14, driven by a $51.4M non-cash fair value change in warrant liabilities. Revenue fell 51% YoY to $2.2M, also below the $2.9M consensus. However, the company highlighted strong pipeline progress (LCA5 pivotal trial enrollment, BEST1 data expected September 2026) and a $90M cash runway into 2029, partially offsetting the headline miss.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.75 vs consensus -$0.14 (212.5% miss)
- Revenue of $2.2M vs consensus $2.9M (51% YoY decline from $4.4M)
- Net loss of $65.5M vs $8.2M in Q1 2025, driven by $51.4M non-cash warrant liability charge
- Cash and equivalents of $60M at March 31, 2026; subsequent $35M senior secured notes + $5M equity from Oberland Capital
- LCA5 program accepted into FDA RDEP program; pivotal Phase 3 trial enrolling
- BEST1 Cohort 1 topline data expected September 2026
- Cash runway into 2029, supporting multiple clinical inflection points
Financial Impact
EPS miss of -$0.61 vs consensus; revenue miss of $0.7M vs consensus; net loss widened by $57.3M YoY primarily due to non-cash warrant liability revaluation
Risk Factors
- Non-cash warrant liability volatility could continue to distort reported earnings
- Revenue concentration on Viatris collaboration (declining 51% YoY)
- Clinical trial risks for LCA5 and BEST1 programs
- Dilution risk from warrant exercises and Series B preferred stock
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 144 | $3.52 | awaiting T+60 | — | $3.41 (−2.98%) |
Oct 21, 2026 5d ago | 8-K | $3.82 | awaiting T+60 | — | $3.41 (−10.60%) |
Oct 15, 2026 11d ago | 8-K | $3.84 | awaiting T+60 | — | $3.41 (−11.07%) |
Oct 15, 2026 11d ago | Press Release | $3.84 | awaiting T+60 | — | $3.41 (−11.07%) |
Sep 22, 2026 4w ago | Institutional Cluster | $5.16 | awaiting T+60 | — | $3.41 (−33.82%) |
Sep 11, 2026 6w ago | 8-K | $6.04 | awaiting T+60 | — | $3.41 (−43.46%) |
Sep 9, 2026 6w ago | 8-K | $5.73 | awaiting T+60 | — | $3.41 (−40.40%) |
Sep 2, 2026 7w ago | Press Release | $4.45 | awaiting T+60 | — | $3.41 (−23.26%) |
Aug 6, 2026 11w ago | 8-K | $3.72 | awaiting T+60 | — | $3.41 (−8.20%) |
Jul 23, 2026 13w ago | 144 | $2.92 $4.05 | ▲ +38.70% | ▲ +34.15% | $3.41 (+16.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers